Shining on Major News: Codexis (NASDAQ:CDXS), Zynga (NASDAQ:ZNGA), CBL & Associates Properties (NYSE:CBL), Montpelier Re Holdings (NYSE:MRH), Arena Pharmaceuticals (NASDAQ:ARNA)

On Thursday shares of Codexis, Inc. (NASDAQ:CDXS) closed at $5.02. Company’s sales growth for last 5 years was -15.70% and EPS growth for next 5 years is recorded as 15.00%. Codexis, Inc. (NASDAQ:CDXS) carries a Zacks Rank #2 (Buy).

On Thursday shares of Zynga, Inc. (NASDAQ:ZNGA) closed at $2.46. Company’s sales growth for last 5 years was 41.50% and EPS growth for next 5 years is recorded as 30.00%. Zynga Inc. (NASDAQ:ZNGA) Chief Executive Officer Mark Pincus is recruiting former colleagues to return to the struggling video-game company, a week after he retook the reins as CEO, according to a person with knowledge of the talks.

On last trading day CBL & Associates Properties Inc. (NYSE:CBL) decreased -0.05% to close at $19.20. Its volatility for the week is 1.25% while volatility for the month is 1.69%. CBL’s sales growth for past 5 years was 0.80% and its EPS growth for past 5 years was 7.20%. CBL & Associates Properties Inc. (NYSE:CBL) monthly performance is 1.48%. CBL & Associates Properties, Inc. (CBL) and Horizon Group Properties, Inc. (HGPI), announced that construction has begun on the second phase of The Outlet Shoppes at Atlanta. The 33,000 square-foot expansion is scheduled to open before the 2015 holiday season and will bring several popular retailers to the center including GAP Outlet and Banana Republic.

Montpelier Re Holdings Ltd. (NYSE:MRH) has 2.40% insider ownership while its institutional ownership stands at 93.20%. In last trading activity company’s stock closed at $39.91. It was reported on 7 April, that Endurance Specialty Holdings Ltd.’s $1.83 billion purchase of Montpelier Re Holdings Ltd. (NYSE:MRH) will likely benefit both reinsurers, according to analysts. The cash-and-stock deal, the latest consolidation move in the Bermuda reinsurance sector, comes nearly a year after Endurance launched its failed attempts to acquire Aspen Insurance Holdings Ltd.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in last trading activity decreased -1.06% to close at $4.66. Company weekly performance is 2.64% while its quarterly performance stands at -17.81%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is -35.46% away from its 52 week high. Arena Pharmaceuticals Inc. (NASDAQ:ARNA), and Eisai Inc. declared the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as contrast to the twice-daily immediate release formulation approved by the US Food and Drug Administration (FDA) and marketed as BELVIQ®.

Leave a Reply

Your email address will not be published. Required fields are marked *

*